Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report published on Friday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

Shares of EGRX opened at $0.71 on Friday. The stock has a fifty day moving average price of $1.21 and a two-hundred day moving average price of $3.40. Eagle Pharmaceuticals has a 52-week low of $0.00 and a 52-week high of $6.81.

Institutional Investors Weigh In On Eagle Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in EGRX. Creative Planning acquired a new position in shares of Eagle Pharmaceuticals during the third quarter worth approximately $59,000. Mackenzie Financial Corp bought a new position in Eagle Pharmaceuticals in the 2nd quarter worth approximately $60,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Eagle Pharmaceuticals in the 2nd quarter worth approximately $65,000. Fidelis Capital Partners LLC acquired a new position in Eagle Pharmaceuticals during the 2nd quarter worth $71,000. Finally, Vanguard Personalized Indexing Management LLC bought a new position in Eagle Pharmaceuticals in the 2nd quarter valued at $76,000. Institutional investors own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.